DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus

References

• World Obesity Federation. World obesity atlas; 2023. Available from: https://data.worldobesity.org/publications/?cat=19. Accessed March 20, 2023.
   Google Scholar
• Caballero B. Humans against obesity: who will win? Adv Nutr. 2019;10(suppl_1):S4–S9. doi:10.1093/advances/nmy055
   PubMedGoogle Scholar
• Aktas G, Atak Tel BM, Tel R, Balci B. Treatment of type 2 diabetes patients with heart conditions. Expert Rev Endocrinol Metab. 2023;18(3):255–265. doi:10.1080/17446651.2023.2204941
   PubMed Web of Science ®Google Scholar
• Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44–58. doi:10.1007/s12325-018-0824-8
   PubMed Web of Science ®Google Scholar
• Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091. doi:10.1038/s41591-022-02026-4
   PubMed Web of Science ®Google Scholar
• Clemmensen C, Finan B, Müller TD, DiMarchi RD, Tschöp MH, Hofmann SM. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat Rev Endocrinol. 2019;15(2):90–104. doi:10.1038/s41574-018-0118-x
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21. doi:10.1111/dom.13129
   PubMed Web of Science ®Google Scholar
• Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57(3):678–687. doi:10.2337/db07-1124
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003;46(6):798–801. doi:10.1007/s00125-003-1103-y
   PubMed Web of Science ®Google Scholar
• Christensen M, Calanna S, Sparre-Ulrich AH, et al. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes. 2015;64(1):72–78. doi:10.2337/db14-0440
   PubMed Web of Science ®Google Scholar
• Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103–3109. doi:10.2337/db11-0979
   PubMed Web of Science ®Google Scholar
• Christensen MB, Calanna S, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(3):E418–26. doi:10.1210/jc.2013-3644
   PubMed Web of Science ®Google Scholar
• Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology. 1978;103(2):610–615. doi:10.1210/endo-103-2-610
   PubMed Web of Science ®Google Scholar
• Rudovich N, Kaiser S, Engeli S, et al. GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. Regul Pept. 2007;142(3):138–145. doi:10.1016/j.regpep.2007.02.006
   PubMedGoogle Scholar
• DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270–1287. doi:10.1007/s00125-010-1684-1
   PubMed Web of Science ®Google Scholar
• Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020;125:170202. doi:10.1016/j.peptides.2019.170202
   PubMed Web of Science ®Google Scholar
• Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. doi:10.1126/scitranslmed.3007218
   PubMed Web of Science ®Google Scholar
• NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ. Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun. 2017;490(2):247–252. doi:10.1016/j.bbrc.2017.06.031
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/nejmoa2107519
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
   PubMed Web of Science ®Google Scholar
• Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD) trial. Expert Rev Endocrinol Metab. 2009;4(2):119–129. doi:10.1586/17446651.4.2.119
   PubMedGoogle Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide--The FDA’s review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774–777. doi:10.1056/nejmp1001578
   PubMed Web of Science ®Google Scholar
• Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: the newest once-weekly GLP-1 RA for type 2 diabetes. Ann Pharmacother. 2018;52(12):1224–1232. doi:10.1177/1060028018784583
   PubMed Web of Science ®Google Scholar
• Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159–166. doi:10.1016/j.tcm.2021.12.008
   PubMed Web of Science ®Google Scholar
• Iepsen EW, Torekov SS, Holst JJ. Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(7):753–767. doi:10.1586/14779072.2015.1054810
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699. doi:10.1001/jama.2015.9676
   PubMed Web of Science ®Google Scholar
• Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563. doi:10.3389/fendo.2021.645563
   PubMed Web of Science ®Google Scholar
• Xie ZY, Yang SS, Deng WS, Li JJ, Chen JS. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clin Epidemiol. 2022;2022(14):1463–1476. doi:10.2147/clep.s391819
   Google Scholar
• Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207–218. doi:10.1517/14740338.2015.987122
   PubMed Web of Science ®Google Scholar
• Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006
   PubMed Web of Science ®Google Scholar
• Lafferty RA, Flatt PR, Irwin N. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opin Pharmacother. 2023;24(5):587–597. doi:10.1080/14656566.2023.2192865
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36(3):498–504. doi:10.2337/dc12-0709
   PubMed Web of Science ®Google Scholar
• Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol. 2013;74(5–6):515–522. doi:10.1016/j.ando.2012.06.002
   PubMed Web of Science ®Google Scholar
• Wang W, Wen X, Duan W, et al. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus. J Endocrinol Invest. 2020;43(5):653–662. doi:10.1007/s40618-019-01153-z
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009
   PubMed Web of Science ®Google Scholar
• Aktas G. Association between the prognostic nutritional index and chronic microvascular complications in patients with type 2 diabetes mellitus. J Clin Med. 2023;12(18):5952. doi:10.3390/jcm12185952
   PubMed Web of Science ®Google Scholar
• Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55. doi:10.1016/j.immuni.2021.12.013
   PubMed Web of Science ®Google Scholar
• Kurtkulagi O. Neutrophil to Lymphocyte ratio is significantly reduced after Sodium glucose cotransporter-2 inhibitor treatment in patients with type 2 diabetes mellitus. Int J Endocrinol. 2022;18(2):86–89. doi:10.22141/2224-0721.18.2.2022.1151
   Google Scholar
• Bendotti G, Montefusco L, Lunati ME, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022;182:106320. doi:10.1016/j.phrs.2022.106320
   PubMed Web of Science ®Google Scholar
• Mantelmacher FD, Zvibel I, Cohen K, et al. GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9. Nat Metab. 2019;1(1):58–69. doi:10.1038/s42255-018-0001-z
   PubMedGoogle Scholar
• Heimbürger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK. Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides. 2020;125:170174. doi:10.1016/j.peptides.2019.170174
   PubMed Web of Science ®Google Scholar